Ehren I. Ekhause

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Ehren

Last Name

Ekhause

NPI

1225400252

Faculty ID

19582

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

78506

Is Open Scheduling

Off

Michael Yee

https://assets.montefioreeinstein.org/profiles/images/13771-michael-yee.jpg

First Name

Michael

Last Name

Yee

NPI

1699971085

Faculty ID

13771

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5456

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Rubiahna L. Vaughn

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/39c87660-56cc-11ee-8e94-bbc6ae6cd7a6.jpg

First Name

Rubiahna

Last Name

Vaughn

NPI

1235490202

Faculty ID

16524

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

100581

Is Open Scheduling

Off

Victoria Vapnyar

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/dd685560-3db5-11ec-b813-25aca5adcea8.jpg

First Name

Victoria

Last Name

Vapnyar

NPI

1740556133

Faculty ID

17135

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

101619

Is Open Scheduling

Off

Lisa B. Teh

https://assets.montefioreeinstein.org/profiles/images/physphoto/Teh_Lisa_PhD_420x504.jpg

First Name

Lisa

Last Name

Teh

NPI

1215243951

Faculty ID

16520

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

121676

Is Open Scheduling

Off

Hina J. Talib

https://assets.montefioreeinstein.org/profiles/images/Talib_Hina_MD_420x504-1.jpg

First Name

Hina

Last Name

Talib

NPI

1306005418

Faculty ID

12509

CMO Specialties

Clinical Terms

Employment Status

Voluntary

Patient Type

Pediatric

Department

Gender

Female

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Hina J. Talib, a Brown University&nbsp;<em>summa cum laude</em>&nbsp;graduate, earned her&nbsp;<em>Bachelor of Science</em>&nbsp;in Neuroscience. She attended medical school at Weill Cornell Medical College, NY where she served as vice-president of her class. She completed her Pediatrics Residency at New York Presbyterian- Weill Cornell and her Chief Residency in Pediatrics at Memorial Sloan Kettering Cancer Center.</p>
<p>Dr. Talib completed a three-year postdoctoral fellowship in Adolescent Medicine in June 2013 at The Children's Hospital at Montefiore. Dr. Talib joined CHAM as Assistant Medical Director for the Michael I. Cohen, MD Adolescent Inpatient Floor where she serves as a teaching hospitalist and chaired the Quality Improvement Committee. In 2015, Dr. Talib was appointed as Associate Director of the Adolescent Medicine Fellowship Training Program. In 2018, Dr. Talib was appointed Medical Director of the Adolescent Inpatient floor.&nbsp;</p>
<p>In addition to providing outpatient sub-specialty care at CHAM, Dr. Talib also cared for youth in foster care at the Children's Aid Society's Bronx Family Health Center. Dr. Talib offers Nexplanon dermal implants, as a method of long acting hormonal contraception, for teen pregnancy prevention at both sites. Her clinical interests include adolescent health, pediatric and adolescent gynecology, contraception, mental health, care of children in foster care, and care of the hospitalized adolescent.</p>
<p>Dr. Talib is board-certified in Pediatrics and in Adolescent Medicine. She is a Fellow of the American Academy of Pediatrics (AAP), and a member of the Society for Adolescent Health and Medicine (SAHM) and the North American Society for Pediatric and Adolescent Gynecology (NASPAG). She serves as Associate Editor of the <em>Journal of Pediatric and Adolescent Gynecology</em>, the official journal of NASPAG, and as a co-chair of the NASPAG resident education committee. In addition, Dr. Talib is a recent past President of the Executive Board of the New York chapter of SAHM.</p>
<p>Dr Talib currently provies pediatric and adolescent medicine care at the Atria Institute.&nbsp;</p>
<p>Connect with Dr. Talib at her website drhinatalib.com or follow Dr. Talib at her instagram @teenhealthdoc.&nbsp;</p>

Research Areas

Research Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Talib's clinical focus is adolescent health, pediatrics and adolescent gynecology, contraception, mental health, care of children in foster care and care of hospitalized adolescents.

Research Focus

Dr. Talib has been studying the effects of Vitamin D deficiency in the adolescent age group since 2012. In 2013, she published a study on influences of partner and relationship factors in HIV testing in Bronx youth. Through her work on the CHAM HIV Testing Task Force, she is currently conducting a quality improvement intervention to increase HIV testing in hospitalized adolescents.

Elsevier Profile

Selected Publications

<p><strong>Talib HJ,</strong> Coupey SM. Excessive Uterine Bleeding. <em>Adolesc Med</em> 2012; 23:53-72</p>
<p><strong>Talib HJ</strong>, Alderman EM.Gynecologic and Reproductive Health Concerns of Adolescents Using Selected Psychotropic Medications. <em>J Pediatr Adolesc Gynecol </em>2013; 26(1):7-15</p>
<p><strong>Talib HJ,</strong> Silver EJ, Coupey SM, Bauman LJ. The influence of individual, partner, and relationship factors in HIV testing in adolescents. <em>AIDS Patient Care STDs</em> 2013; 27(11): 637-4</p>
<p><strong>Talib HJ</strong>, Ponnapakkam T, Gensure R, Cohen HW, Coupey SM. Treatment of vitamin D deficiency in predominantly Hispanic and black adolescents: a randomized clinical trial. <em>J Pediatr</em> 2016; 170:266-72. PMID: 26707619</p>
<p><strong>Talib HJ</strong><span style="text-decoration: underline;">,</span> Silver EJ, Alderman EM. Challenges to adolescent confidentiality in a children&rsquo;s hospital. <em>Hosp Pediatr</em> 2016; 6(8):490-5. PMID: 27461762</p>
<p>Fleming N, Aimes-Oeschlager A, Browner-Elhanan KJ, Kaul P, <strong>Talib HJ</strong>, Wheeler C, Loveless M. Resident Education Curriculum in Pediatric and Adolescent Gynecology: The Short Curriculum. <em>J Pediatr Adolesc Gynecol </em>2014; 27(2):117-20</p>
<p><strong>Talib HJ</strong>, Karjane N, Teelin K, Abraham M, Holt S, Chelvakumar G, Dumont T, Huguelet PS, Connor L, Wheeler C, Fleming N. Resident education curriculum in pediatric and adolescent gynecology: the short curriculum 2.0. <em>J Pediatr Adolesc Gynecol</em>&nbsp;2018; 31(2):71-76</p>
<p>Bhalakia AM, <strong>Talib HJ</strong>, Choi J, Watnick D, Bochner R, Futterman D, Gross E. Acceptance of routine HIV testing by hospitalized adolescents and young adults. <em>Hospital Pediatr</em> 2018; 8(4):187-193. PMID:29599198</p>

Biography

<p>Hina J. Talib, MD, is Director of the Adolescent Medicine Fellowship Program and an Attending Physician in the Division of Adolescent Medicine at Children&rsquo;s Hospital at Montefiore. Dr. Talib is also an Associate&nbsp;Professor of Pediatrics at our Albert Einstein College of Medicine. Her clinical focus is adolescent health, pediatrics and adolescent gynecology, contraception, mental health, care of children in foster care and care of hospitalized adolescents. She joined the Montefiore team in 2013.</p><p>Dr. Talib received her Bachelor of Science in Neuroscience in 2001 from Brown University. In 2006, she received her Doctor of Medicine from Weill Cornell Medical College of Cornell University. In 2009, Dr. Talib completed a residency in pediatrics at New York Presbyterian Phyllis and David Komansky Center for Children&rsquo;s Health &ndash; Weill Cornell Medical Center. She became Chief Resident in Pediatrics at Memorial Sloan Kettering Cancer Center that same year. Dr. Talib went on to complete a postdoctoral fellowship in Adolescent Medicine at CHAM in 2013.</p><p>Dr. Talib has been studying the effects of Vitamin D deficiency in the adolescent age group since 2012. In 2013, she published a study on influences of partner and relationship factors in HIV testing in Bronx youth. Through her work on the CHAM HIV Testing Task Force, she is currently conducting a quality improvement intervention to increase HIV testing in hospitalized adolescents. Her work has been published numerous times in peer reviewed journals, review articles, and books and has been presented at national meetings.</p><p>In 2014, Dr. Talib won Best Platform Presentation for her work, &ldquo;Randomized Clinical Trial of Two High-dose vs. Low-dose Treatment Regimens for Vitamin D Deficiency in Minority Adolescents Living in a Northeast City&rdquo; at Pediatric Research Day at CHAM.</p><p>Dr. Talib is board certified by the American Board of Pediatrics and is a member of the American Academy of Pediatrics, Section in Adolescent Health.</p>

Is Open Scheduling

Off

Asli S. Sucu

https://assets.montefioreeinstein.org/profiles/images/16076-asli-sucu.jpg

First Name

Asli

Last Name

Sucu

NPI

1477815934

Faculty ID

16076

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

55869

Is Open Scheduling

Off

Martina Stehlikova

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Martina

Last Name

Stehlikova

NPI

1033392493

Faculty ID

13031

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>In-patient internal medicine with a special interest in hematology. Anemia, thrombocytopenia and coagulopathy in hospitalised patients.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5287

Is Open Scheduling

Off

Brian D. Spund

https://assets.montefioreeinstein.org/profiles/images/physphoto/Spund_Brian_D._MD_11121354.jpg

First Name

Brian

Last Name

Spund

NPI

1629377320

Faculty ID

15059

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

68828

Is Open Scheduling

Off